Halie Frideres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Halie Frideres has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bryant R. England
VA Nebraska‐Western Iowa Health Care System and University of Nebraska Medical Center Omaha Nebraska
4 shared publications Joshua F. Baker
Corporal Michael J. Crescenz VA Medical Center Philadelphia Pennsylvania
4 shared publications- Grant W. Cannon
VA Salt Lake City Health Care System and University of Utah Salt Lake City
3 shared publications Punyasha Roul
Division of Rheumatology & Immunology University of Nebraska Medical Center Omaha
3 shared publicationsScott M. Matson
Kansas University Medical Center Kansas City
3 shared publications- Ted R. Mikuls
University of Nebraska Medical Center Omaha
3 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Wiley in Arthritis Care & Research
Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis–Associated Interstitial Lung Disease Risk
Objective: The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase‐7 (MMP‐7), and serum anti–malondialdehyde‐acetaldehyde (anti‐MAA) antibody for rheumatoid arthritis (RA)–associated interstitial lung disease (ILD) risk stratification. Methods: Using a multicenter cohort of US veterans with RA, we performed a cross‐sectional study of prevalent RA‐ILD and a cohort study of incident RA‐ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three‐biomarker score (range 0–3) was calculated based on the presence of the MUC5B variant and elevations (upper 25% vs lower 75%) in MMP‐7 and anti‐MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors. Results: Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male; mean age 63.6 years). The odds of prevalent RA‐ILD were higher with increased biomarker score (adjusted odds ratio 12.21 [95% confidence interval (CI) 3.82–38.97] for score of 3 vs 0). A score ≥1 had 76.1% sensitivity but 48.6% specificity. Incident RA‐ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (adjusted hazard ratio 4.36 [95% CI 1.55–12.27]). The area under the curve for prevalent RA‐ILD and Harrell's C for incident RA‐ILD were highest when clinical risk factors were combined with the biomarker score. Conclusion: This three‐analyte biomarker score was associated with both prevalent and incident RA‐ILD, improving risk stratification beyond clinical risk factors. Although this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA‐ILD risk stratification.
- 24 February 2026
- Published by Wiley in Arthritis Care & Research
Open AccessCombining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis–Associated Interstitial Lung Disease Risk
Objective: The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase‐7 (MMP‐7), and serum anti–malondialdehyde‐acetaldehyde (anti‐MAA) antibody for rheumatoid arthritis (RA)–associated interstitial lung disease (ILD) risk stratification. Methods: Using a multicenter cohort of US veterans with RA, we performed a cross‐sectional study of prevalent RA‐ILD and a cohort study of incident RA‐ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three‐biomarker score (range 0–3) was calculated based on the presence of the MUC5B variant and elevations (upper 25% vs lower 75%) in MMP‐7 and anti‐MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors. Results: Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male; mean age 63.6 years). The odds of prevalent RA‐ILD were higher with increased biomarker score (adjusted odds ratio 12.21 [95% confidence interval (CI) 3.82–38.97] for score of 3 vs 0). A score ≥1 had 76.1% sensitivity but 48.6% specificity. Incident RA‐ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (adjusted hazard ratio 4.36 [95% CI 1.55–12.27]). The area under the curve for prevalent RA‐ILD and Harrell's C for incident RA‐ILD were highest when clinical risk factors were combined with the biomarker score. Conclusion: This three‐analyte biomarker score was associated with both prevalent and incident RA‐ILD, improving risk stratification beyond clinical risk factors. Although this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA‐ILD risk stratification.
- Open Access
- 17 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (7) , 1437-1445
Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis
Objective: Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). Methods: Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006–2020). Ten‐year estimated cardiovascular disease (CVD) risk was calculated using PREVENT. Calibration (standardized incidence ratio [SIR] and observed/predicted events) and discrimination (sensitivity and Harrel's C‐statistics) were compared between RA cases and controls. PREVENT performance was compared with the Pooled Cohort Equations (PCE) for atherosclerotic CVD (ASCVD) prediction in RA, including net reclassification index (NRI) calculation. Results: Among 30,687 patients with RA and 231,752 patients without RA, 28,061 ASCVD and 13,851 heart failure (HF) outcomes were identified over >2 million person‐years. PREVENT underestimated overall CVD (SIR 1.83, 95% confidence interval [CI] 1.79–1.88), ASCVD (SIR 2.25, 95% CI 2.19–2.32) and HF risk (SIR 1.41, 95% CI 1.36–1.46) to a greater degree in RA compared with controls and exhibited poor sensitivity for ASCVD (61.9%) and HF (63.2%) development. PREVENT performance was poorer for ASCVD prediction compared with the PCE (SIR 1.38, 95% CI 1.34–1.41, sensitivity 76.0%). NRI for PREVENT was modest (5.3%). Among 657 reclassified patients who experienced ASCVD, 626 were inappropriately reclassified as low or borderline risk. PREVENT performance significantly improved when including hemoglobin A1c (overall CVD: SIR 1.21, 95% CI 1.18–1.24; ASCVD: SIR 1.45, 95% CI 1.41–1.50; HF: SIR 0.79, 95% CI 0.76–0.82; sensitivity ASCVD 80.3%). Conclusion: PREVENT underestimates CVD risk in RA, consistent with suboptimal performance of existing risk calculators. Preferential use of PREVENT including hemoglobin A1c should be considered. Improving CVD risk stratification in RA remains a high priority.
- 17 February 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (7) , 1437-1445
Open AccessPerformance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis
Objective: Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). Methods: Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006–2020). Ten‐year estimated cardiovascular disease (CVD) risk was calculated using PREVENT. Calibration (standardized incidence ratio [SIR] and observed/predicted events) and discrimination (sensitivity and Harrel's C‐statistics) were compared between RA cases and controls. PREVENT performance was compared with the Pooled Cohort Equations (PCE) for atherosclerotic CVD (ASCVD) prediction in RA, including net reclassification index (NRI) calculation. Results: Among 30,687 patients with RA and 231,752 patients without RA, 28,061 ASCVD and 13,851 heart failure (HF) outcomes were identified over >2 million person‐years. PREVENT underestimated overall CVD (SIR 1.83, 95% confidence interval [CI] 1.79–1.88), ASCVD (SIR 2.25, 95% CI 2.19–2.32) and HF risk (SIR 1.41, 95% CI 1.36–1.46) to a greater degree in RA compared with controls and exhibited poor sensitivity for ASCVD (61.9%) and HF (63.2%) development. PREVENT performance was poorer for ASCVD prediction compared with the PCE (SIR 1.38, 95% CI 1.34–1.41, sensitivity 76.0%). NRI for PREVENT was modest (5.3%). Among 657 reclassified patients who experienced ASCVD, 626 were inappropriately reclassified as low or borderline risk. PREVENT performance significantly improved when including hemoglobin A1c (overall CVD: SIR 1.21, 95% CI 1.18–1.24; ASCVD: SIR 1.45, 95% CI 1.41–1.50; HF: SIR 0.79, 95% CI 0.76–0.82; sensitivity ASCVD 80.3%). Conclusion: PREVENT underestimates CVD risk in RA, consistent with suboptimal performance of existing risk calculators. Preferential use of PREVENT including hemoglobin A1c should be considered. Improving CVD risk stratification in RA remains a high priority.
- Open Access
- 11 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (2) , 302-310
Performance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease
Objective: To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) using three independent cohorts. Methods: We first assessed the association of a panel of IPF‐associated biomarkers with prevalent ILD among two separate RA cohorts (n = 93 and n = 71). Concentrations of eight IPF‐related biomarkers (eotaxin, Flt‐3L, interleukin‐8, macrophage‐derived chemokine, monocyte chemoattractant protein 1, and matrix metalloproteinase 2/7/9 [MMP‐2/7/9]) were measured, standardized, and summed to generate a multibiomarker score. We subsequently validated the association of this score (minus MMP‐2) with prevalent and incident ILD in an independent multicenter prospective cohort of US veterans with RA (n = 2,507). Multivariable regression models were adjusted for relevant covariates in the validation cohort. Results: In both development cohorts, participants with RA‐ILD had significantly higher IPF multibiomarker scores than those with RA alone. In the independent validation cohort, participants in the highest quartile of multibiomarker scores had a significantly higher likelihood of prevalent ILD (adjusted odds ratio 2.14 [95% confidence interval 1.18–3.87]) and incident ILD (adjusted hazard ratio 2.45 [95% confidence interval 1.55–3.88]) than those in the lowest quartile. The cumulative hazard of incident ILD approached 20% by 15 years for those in the highest quartile, compared to <10% for all other quartiles. Conclusion: A multibiomarker panel derived from IPF‐associated biomarkers was associated with RA‐ILD in separate development and validation cohorts. This overlap supports the concept of shared etiopathogenesis of IPF and RA‐ILD and illustrates the potential for peripheral blood biomarker panels to stratify ILD risk among patients with RA.
- 11 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (2) , 302-310
Open AccessPerformance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease
Objective: To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) using three independent cohorts. Methods: We first assessed the association of a panel of IPF‐associated biomarkers with prevalent ILD among two separate RA cohorts (n = 93 and n = 71). Concentrations of eight IPF‐related biomarkers (eotaxin, Flt‐3L, interleukin‐8, macrophage‐derived chemokine, monocyte chemoattractant protein 1, and matrix metalloproteinase 2/7/9 [MMP‐2/7/9]) were measured, standardized, and summed to generate a multibiomarker score. We subsequently validated the association of this score (minus MMP‐2) with prevalent and incident ILD in an independent multicenter prospective cohort of US veterans with RA (n = 2,507). Multivariable regression models were adjusted for relevant covariates in the validation cohort. Results: In both development cohorts, participants with RA‐ILD had significantly higher IPF multibiomarker scores than those with RA alone. In the independent validation cohort, participants in the highest quartile of multibiomarker scores had a significantly higher likelihood of prevalent ILD (adjusted odds ratio 2.14 [95% confidence interval 1.18–3.87]) and incident ILD (adjusted hazard ratio 2.45 [95% confidence interval 1.55–3.88]) than those in the lowest quartile. The cumulative hazard of incident ILD approached 20% by 15 years for those in the highest quartile, compared to <10% for all other quartiles. Conclusion: A multibiomarker panel derived from IPF‐associated biomarkers was associated with RA‐ILD in separate development and validation cohorts. This overlap supports the concept of shared etiopathogenesis of IPF and RA‐ILD and illustrates the potential for peripheral blood biomarker panels to stratify ILD risk among patients with RA.